CSIMarket
 
Zeo Scientifix Inc   (BPSR)
Other Ticker:  
 
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 6
 Employees -
 Revenues (TTM) (Millions $) 5
 Net Income (TTM) (Millions $) -5
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Zeo Scientifix Inc
Organicell Regenerative Medicine Inc. is a biotechnology company specializing in regenerative medicine. The company focuses on developing innovative therapies using biological products derived from natural sources. Organicell's mission is to harness the healing power of nature to provide effective treatment options for patients suffering from various medical conditions.

The company's research and development efforts are centered around utilizing the regenerative properties of exosomes, which are small extracellular vesicles secreted by cells. These exosomes are rich in growth factors, proteins, and nucleic acids that have the potential to stimulate tissue repair and regeneration.

Organicell aims to develop exosome-based therapies for a range of diseases and disorders, including neurodegenerative conditions, cardiovascular diseases, and orthopedic injuries. By harnessing the potential of exosomes, the company aims to provide safer and more efficient treatment options that can potentially address the underlying causes of these conditions.

Organicell also places a strong emphasis on the safety and efficacy of its products. The company follows rigorous research, development, and manufacturing protocols to ensure the quality and consistency of its therapies. Through collaborations with leading academic institutions and clinical research organizations, Organicell aims to advance the field of regenerative medicine and improve patient outcomes.

In summary, Organicell Regenerative Medicine Inc. is a biotechnology company focused on developing innovative therapies using exosomes derived from natural sources. The company aims to harness the healing power of these biological products to provide effective treatment options for various medical conditions.


   Company Address: 3321 College Avenue Davie 33314 FL
   Company Phone Number: 963-7881   Stock Exchange / Ticker: BPSR


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AURA   -3%    
BCDA   -10.51%    
BLUE   -9.63%    
FATE   -11.97%    
LCTX   -0.59%    
RGNX   -6.41%    
• View Complete Report
   



Zeo Scientifix Inc

Zeo Scientific Inc Reports Alarming Q3 Shortfall: A Deeper Dip Than Last Year in Biotechnology & Pharmaceuticals


Zeo Scientifix Inc. Reports Q3 2024 Earnings: A Mixed Picture Amid Industry Growth
Zeo Scientifix Inc., a player in the biotechnology and pharmaceuticals sector, recently released its earnings report for the third quarter of 2024. The results reveal a complex financial landscape for the company, marked by increased losses, declining revenue, and contrasting trends within the broader industry.


Earnings Overview
In the third quarter of 2024, Zeo Scientifix reported a loss of $0.16 per share, a significant decrease from the breakeven point of $0.00 per share recorded in the same quarter of the previous year. However, this figure is an improvement from the preceding quarter?s loss of $0.23 per share, suggesting that while losses are still present, there is a trend towards minimizing them.

Zeo Scientifix Inc

Zeo Scientifix Inc Struggles to Translate Revenue Surge into Profitability in Latest Fiscal Period



Zeo Scientifix Inc is facing a challenging time as its financial performance reveals a mixed bag of results. Despite a notable increase in revenue, the company has experienced a significant shortfall per share. This article aims to critically analyze Zeo Scientifix Inc's recent fiscal period ending April 30, 2024, and delve into the concerning discrepancy between revenue growth and increasing net shortfalls.
Dissecting the Financial Data:
BPSR, the commonly used ticker symbol for Zeo Scientifix Inc, disclosed a loss per share of $-0.23 in the fiscal period ending April 30, 2024. This represents a deteriorating situation compared to the prior financial reporting period, where the loss per share was $-0.17. The company's shareholders should be wary of this decline, as it raises questions about management's ability to control costs and improve profitability.

Zeo Scientifix Inc

BPSR Achieves Stable Growth Over Three-Month Period Ending January 31, 2024

Zeo Scientifix Inc has shown promising growth in its recent financial results, despite reporting a deficit per share of $-0.17 for the span ending January 31, 2024. This is a significant improvement from the deficit of $-2.287 million in the same period a year ago. The company's revenue also saw a healthy increase of 7.828% to $1.15 million, showing strong growth potential.
One key highlight of the financial report is the notable increase in inventories and supplies, which now stand at $0.3 million. This indicates that the company is investing in its operations and preparing for future growth. Additionally, the decrease in accounts receivable compared to the previous year suggests that the company is effectively managing its cash flow and collections.

Organicell Regenerative Medicine Inc

Organicell Regenerative Medicine Inc. Overcomes Challenges, Shows Resilience During Recent Fiscal Period

Organicell Regenerative Medicine Inc Reaches Break-Even in Q3 2023
During the third quarter of 2023, Organicell Regenerative Medicine Inc reached a break-even point of $0.00 per share, compared to the same period last year and the preceding reporting period. This achievement indicates the company's ability to generate revenue to cover its expenses.
However, the company experienced a significant decline in revenue, which crumbled by -28.749% to $1.22 million from $1.71 million during the comparable reporting period a year ago. On the positive side, there was a sequential revenue surge of 44.373% from $0.85 million. This indicates that, while the year-over-year comparison may seem negative, the company has seen substantial growth compared to the previous quarter.
Organicell Regenerative Medicine Inc reported a net shortfall of $-1.618 million in the third quarter of 2023, which is an improvement from a deficit of $-2.727 million in the same reporting period a year ago. This reduction in the net shortfall indicates that the company has managed to control its expenses better, leading to a smaller financial deficit.

Organicell Regenerative Medicine Inc

Organicell Regenerative Medicine Inc Suffers Dire Revenue Plunge of Over 50% as Fiscal Interval Concludes April 2023

Organicell Regenerative Medicine Inc, a leading company in the field of regenerative medicine, recently released its financial report for the span closing April 30, 2023. The company demonstrated balanced books, with earnings of $0.00 per share. This figure remained the same as the previous year, and there was no change from the prior reporting season.
However, amidst this seemingly stable financial standing, there was a significant decline in revenue. Compared to the same reporting season a year earlier, Organicell saw a sharp decrease of -51.273%, generating $0.85 million in revenue, down from $1.74 million. Sequentially, the company experienced a -20.997% decrease in revenue, with $1.07 million generated in the prior reporting season.







Zeo Scientifix Inc's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com